In spite of its potential therapeutic benefit for patients affected by hematologic malignancies, the mechanism underlying H3B’s preferential lethality towards mutant cancer cells bearing the K700E-SF3B1 (K700ESF3B1) mutation remains unclear at the molecular level. The gene discussed is SF3B1; the disease is hematologic disorder.